Get the Stockscreener App
0.639
1.31%
-0.0085
After Hours:
.66
0.021
+3.29%
Immunoprecise Antibodies Ltd stock is traded at $0.639, with a volume of 1.05M.
It is down -1.31% in the last 24 hours and down -15.36% over the past month.
ImmunoPrecise Antibodies Ltd is a supplier of custom antibodies to the research industry and industrial community. The company has aggregated its operations into one reportable segment, Antibody Production, and Related Services. It operates in three principal geographical areas - the United States of America, Canada, Europe, Australia and others. The majority of its revenue is derived from United States of America.
See More
Previous Close:
$0.6475
Open:
$0.67
24h Volume:
1.05M
Relative Volume:
7.44
Market Cap:
$17.84M
Revenue:
$16.77M
Net Income/Loss:
$-11.87M
P/E Ratio:
-1.0208
EPS:
-0.626
Net Cash Flow:
$-5.90M
1W Performance:
-0.55%
1M Performance:
-15.36%
6M Performance:
-57.96%
1Y Performance:
-65.08%
1-Day Range:
$0.6026
$0.6901
1-Week Range:
$0.5882
$0.6901
52-Week Range:
$0.53
$2.60
Immunoprecise Antibodies Ltd Stock (IPA) Company Profile
Name
Immunoprecise Antibodies Ltd
Sector
Industry
Phone
-
Address
-
Immunoprecise Antibodies Ltd Stock (IPA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-22 | Initiated | H.C. Wainwright | Buy |
| Oct-25-21 | Initiated | The Benchmark Company | Buy |
Immunoprecise Antibodies Ltd Stock (IPA) Latest News
ImmunoPrecise’s Breakthroughs in Cancer Antibody Therapies - TipRanks
ImmunoPrecise Antibodies Advances Therapeutic Innovation with Groundbreaking Rabbit Antibody Developments - StockTitan
ImmunoPrecise Antibodies Advances Therapeutic Innovation with Groundbreaking Rabbit Antibody Developments - Business Wire
ImmunoPrecise Sets Virtual Annual General Meeting - TipRanks
Ratio Review: Analyzing ImmunoPrecise Antibodies Ltd (IPA)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Was ImmunoPrecise Antibodies Ltd (IPA)’s session last reading good? - US Post News
ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Q1 2025 Earnings Call Transcript - Insider Monkey
ImmunoPrecise Unveils Executive Compensation Strategy - TipRanks
IPA Stock Update: ImmunoPrecise Antibodies Ltd’s Banking’s Market Struggles and Potential Opportunities - The InvestChronicle
Earnings call: ImmunoPrecise announces mixed Q1 results, eyes future growth - Investing.com Australia
Earnings call: ImmunoPrecise announces mixed Q1 results, eyes future growth - Investing.com
Post-Trade Analysis: ImmunoPrecise Antibodies Ltd (IPA) Slides -19.12, Closing at 0.54 - The Dwinnex
ImmunoPrecise Antibodies Ltd (IPA) Q1 2025 Earnings Call Transcript Highlights: Revenue Growth ... - Yahoo Finance UK
ImmunoPrecise Antibodies Ltd (IPA) Q1 2025 Earnings Call Transcript Highlights: Revenue Growth ... By GuruFocus - Investing.com Canada
ImmunoPrecise Antibodies Ltd. (IPA) Reports Q1 Loss, Misses Revenue Estimates - MSN
ImmunoPrecise Antibodies Ltd. (IPA) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
ImmunoPrecise Achieves AI-Driven Growth Amidst Challenges - TipRanks
ImmunoPrecise Advances Biotherapeutic Research Efficiency - TipRanks
ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025 - Business Wire
Earnings To Watch: ImmunoPrecise Antibodies Ltd (IPA) Reports Q1 2025 Result - GuruFocus.com
ImmunoPrecise Announces Upcoming Earnings Call - TipRanks
IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025 on September 16, 2024 - Business Wire
ImmunoPrecise Joins Prestigious Global Investment Conference - TipRanks
ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York - Business Wire
ImmunoPrecise Antibodies Receives Nasdaq Notification Regarding Minimum Bid Requirements - StockTitan
ImmunoPrecise Antibodies Receives Nasdaq Notification Regarding Minimum Bid Requirements - Business Wire
ImmunoPrecise Antibodies Successfully Engineers in silico Antibodies to Elusive Tumor Protein Using Its Patented LENSai Technology - Chronicle-Tribune
ImmunoPrecise Antibodies Successfully Engineers in silico Antibodies to Elusive Tumor Protein Using Its Patented LENSai Technology - StockTitan
ImmunoPrecise Antibodies Successfully Engineers in silico Antibodies to Elusive Tumor Protein Using Its Patented LENSai Technology - Yahoo Finance
Short Interest in ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Declines By 14.4% - Defense World
Benchmark Lowers ImmunoPrecise Antibodies (NASDAQ:IPA) Price Target to $3.00 - Defense World
Immunoprecise shares target cut, rating held on market volatility - Investing.com
Immunoprecise shares target cut, rating held on market volatility - Investing.com India
Immunoprecise shares target cut, rating held on market volatility By Investing.com - Investing.com Australia
ImmunoPrecise Antibodies (STU:TQB) Forward Dividend Yield % : 0.00% (As of Aug. 16, 2024) - GuruFocus.com
Q1 2025 EPS Estimates for ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Cut by HC Wainwright - Defense World
Equities Analysts Set Expectations for ImmunoPrecise Antibodies Ltd.’s FY2029 Earnings (NASDAQ:IPA) - Defense World
Earnings call: ImmunoPrecise Reports Record Revenue in Q4 and Fiscal Year 2024 - Investing.com India
ImmunoPrecise Antibodies Ltd. (IPA) Q4 2024 Earnings Call Transcript - Seeking Alpha
ImmunoPrecise Antibodies Ltd. (IPA) Reports Q4 Loss, Lags Revenue Estimates - MSN
ImmunoPrecise Antibodies Ltd. (IPA) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance UK
ImmunoPrecise Antibodies Achieves Record Revenue - TipRanks
ImmunoPrecise Antibodies (IPA) Reports Financial Results and Business Updates for Fourth Quarter and Full Fiscal Year 2024 - Business Wire
ImmunoPrecise Delays Annual Financial Results Release - TipRanks
ImmunoPrecise Antibodies to Reschedule Financial Results and Recent Business Highlights Report for Fourth Quarter and Fiscal Year-End 2024 - Business Wire
ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Short Interest Down 8.0% in June - Defense World
ImmunoPrecise Antibodies (IPA) to Release Quarterly Earnings on Thursday - Defense World
ImmunoPrecise Announces Financing Agreement with Yorkville Advisors Global, LP of up to $3.0 Million Aggregate Principal Amount of Convertible Debentures - StockTitan
ImmunoPrecise Announces Financing Agreement with Yorkville Advisors Global, LP of up to $3.0 Million Aggregate Principal Amount of Convertible Debentures - Business Wire
IPAImmunoPrecise Antibodies Ltd. Latest Stock News & Market Updates - StockTitan
ImmunoPrecise to Announce FY 2024 Results - TipRanks
Immunoprecise Antibodies Ltd Stock (IPA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):